Quantcast
Are you getting the best rate from your broker?
Compare your broker's rates now to find out if you can save money

Choose your broker below
Welcome to Dividend.com. Please help us personalize your experience.

Select the one that best describes you
ALERT

Memorial Day Sale: Dividend.com Premium Price Slashed — Redeem Now

Dividend logo

The major pharmaceutical companies are facing quite a predicament. Billions of dollars worth of patent-protected drugs have already gone or are preparing to go generic over the next few years. Dubbed the “patent cliff”, the loss of these blockbusters and other major money-making drugs for the largest pharmaceutical companies is enough to make any investor cringe. For dividend investors, it’s especially troublesome as some of these drugs have been the driving force behind Big Pharma’s status as dividend safe havens.

Rather than resignedly driving over the cliff, Big Pharma has at least begun to pump the brakes and look for alternatives. As a result, Big Pharma has found itself diving head first into biotech manufacturers and their lucrative cures for rare diseases.

Except, it turns out that biotech may not be the panacea they hoped for. Regulation and public scorn could crimp the ability of the biotechs – and correspondingly Big Pharma – to charge an arm and a leg for the medications.

To read the Full Story, Go Premium or Log In

Popular Articles

Premium Shutterstock 287237753
News

The Commodities Rally Could Keep Going

As they say in the markets, this year’s losers will be next year’s winners. However,...

Premium Shutterstock 593856878%20%281%29
News

The Market Wrap For May 26: Game On!

Politics – or in this case, the lack of – continues to be a primary driver of the market’s...

News

Trending: U.S.-Saudi Arabia Weapons Deal Drives Defense Stocks

Dividend.com analyzes the search patterns of our visitors each week. By sharing these trends with...